Article Information
History
- August 13, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Charles C.T Hindmarch1,2,3,
- François Potus4,
- Al-Qazazi Ruaa2,
- Brooke Ring3,
- William C Nichols5,
- Michael J Rauh6 and
- Stephen L Archer2,3,*
- 1Department of Biomedical and Molecular Science (DBMS), Queen’s University, Kingston, Ontario
- 2Department of Medicine, Queen’s University, Kingston, Ontario
- 3Queen’s CardioPulmonary Unit, Translational Institute of Medicine, Department of Medicine, Queen’s University, Kingston, Ontario, Canada
- 4Pulmonary Hypertension Research Group, Center de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, QC, Canada
- 5Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics; University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
- 6Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
- ↵*Corresponding Author:
Archer Stephen L, MD; Queen’s University, Kingston, Ontario, Canada. Professor, Scientific Director of the Translational Institute of Medicine (TIME), Queen’s University, Etherington Hall, Room 3041. 94 Stuart St., Kingston, Ontario, Canada, K7L 3N6. email: stephen.archer{at}queensu.ca
Posted August 13, 2023.
Humans with Pulmonary Arterial Hypertension display a global hypermethylation signature that worsens in patients who have a mutation in the gene encoding the methylation eraser, Tet Methylcytosine Dioxygenase 2 (TET2)
